Want to see LNTH full AI Analyst Report?
Top Page
Lantheus
(NASDAQ:LNTH)
Select Model
Select Model
Rating:72Outperform
Price Target:
$113.00
▲(7.80% Upside)
Action:Reiterated
Date:08/06/26
LNTH’s score is driven primarily by strong financial performance, led by robust operating and free cash flow generation and solid operating margins, partially offset by net income volatility and moderate leverage. Corporate events are supportive due to the announced take-private deal with cash consideration and CVR upside. Technical signals are mixed (negative MACD and below short-term moving averages), while valuation is moderate with no dividend yield support included. Earnings call tone is balanced: guidance was reaffirmed and regulatory progress noted, but near-term margin and competitive pressures remain.
Positive Factors
Cash generation
Sustained high operating and free cash flow provides durable internal funding for commercialization, manufacturing scale-up, and R&D without relying on equity issuance. This supports meeting CVR-linked milestones, servicing debt, and funding integration or new product launches over the next 2–6 months.
Negative Factors
Net income volatility
Below-the-line volatility driven by nonrecurring charges, amortization and other adjustments makes earnings less predictable. That unpredictability can complicate covenant management, CVR achievement forecasting, and capital-allocation planning across the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation
Sustained high operating and free cash flow provides durable internal funding for commercialization, manufacturing scale-up, and R&D without relying on equity issuance. This supports meeting CVR-linked milestones, servicing debt, and funding integration or new product launches over the next 2–6 months.
Read all positive factors
Lantheus (LNTH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.59B
Dividend YieldN/A
Average Volume (3M)876.53K
Price to Earnings (P/E)24.0
Beta (1Y)0.42
Revenue Growth2.35%
EPS Growth7.38%
CountryUS
Employees1,193
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.21
Shares Outstanding65,272,370
10 Day Avg. Volume728,106
30 Day Avg. Volume876,534
Financial Highlights & Ratios
PEG Ratio-0.82
Price to Book (P/B)4.12
Price to Sales (P/S)2.91
P/FCF Ratio12.69
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$105.40Price Target Upside0.55% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)5.35
Revenue Forecast (FY)$1.48B
Lantheus Business Overview & Revenue Model
Company Description
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis...
How the Company Makes Money
Lantheus makes money primarily by selling diagnostic imaging agents (radiopharmaceuticals and related imaging products) to healthcare providers (e.g., hospitals, imaging centers) and distributors, generating product revenue per dose/unit shipped. ...
Lantheus Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Neutral
The call contained meaningful positives — regulatory progress with PYLARIFY TRUVU approval, solid cash generation, NEUROCEQ and DEFINITY growth, and a reaffirmed full-year outlook — balanced against near-term profitability pressure driven by lower oncology reported revenue, higher operating expenses from recent acquisitions and investments, competitive and pricing risks in PSMA PET, and regulatory timing uncertainty for some therapeutic assets. Management emphasized disciplined capital allocation and readiness to launch TRUVU, and expects growth acceleration in 2027, but near-term headwinds keep the tone measured.Positive Updates
FDA Approval of PYLARIFY TRUVU
FDA approved PYLARIFY TRUVU on March 6, 2026. The new formulation offers larger batch sizes and improved stability at higher radioactive concentrations, enabling broader geographic reach and supply flexibility. Management estimates >70% of current PYLARIFY supply is produced at PMF sites equipped to realize TRUVU advantages.
Negative Updates
Oncology Revenue Decline (PYLARIFY reported revenue)
Oncology revenue (PYLARIFY) was $240.9 million in Q1, down 6.5% year-over-year despite volume growth, reflecting net price pressure and competitive dynamics in the PSMA PET space.
Read all updates
Q1-2026 Updates
Positive
Negative
FDA Approval of PYLARIFY TRUVU
FDA approved PYLARIFY TRUVU on March 6, 2026. The new formulation offers larger batch sizes and improved stability at higher radioactive concentrations, enabling broader geographic reach and supply flexibility. Management estimates >70% of current PYLARIFY supply is produced at PMF sites equipped to realize TRUVU advantages.
Read all positive updates
Company Guidance
Lantheus reiterated full‑year 2026 guidance of $1.40–$1.45 billion in revenue and $5.00–$5.25 in adjusted EPS while citing a strong Q1 start: Q1 revenue $377.3M (+1.2% YoY; +8.6% ex‑$25.2M divested spec revenue), reported net income $118.4M and adjusted net income $95.8M (‑12.5% YoY), GAAP diluted EPS $1.80 and adjusted EPS $1.46 (down ~4.6%), operating profit $129.1M (‑10.5%), gross margin 67.0%, operating expenses 32.8% of revenue, and an effective tax rate of 25.3%; product level Q1 results included PYLARIFY $240.9M (‑6.5% YoY; U.S. volume +5.8% YoY), NEUROCEQ $35.4M (+14.3% vs Q4 2025), DEFINITY $84.6M (+6.8% YoY) and strategic partnerships $16.3M (+52.1%). Cash generation remained strong with operating cash flow $125.1M, capex $3.2M, free cash flow $121.9M, cash & equivalents $498.6M, $200M remaining on the buyback authorization and a $750M undrawn revolver; management said guidance is being maintained out of prudence given competitive dynamics and an upcoming CEO transition, while expecting growth acceleration beginning in 2027.Lantheus Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
67
Positive
Cash Flow
86
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.56B | 1.54B | 1.53B | 1.30B | 935.06M | 425.21M |
| Gross Profit | 936.02M | 941.95M | 988.29M | 709.54M | 581.70M | 187.69M |
| EBITDA | 465.39M | 403.64M | 515.27M | 491.00M | 81.83M | -25.00M |
| Net Income | 275.31M | 233.56M | 312.44M | 326.66M | 28.07M | -71.28M |
Balance Sheet | ||||||
| Total Assets | 2.41B | 2.23B | 1.98B | 1.65B | 1.32B | 863.78M |
| Cash, Cash Equivalents and Short-Term Investments | 593.30M | 359.12M | 912.81M | 713.66M | 415.65M | 98.51M |
| Total Debt | 624.96M | 619.43M | 619.44M | 616.95M | 583.51M | 191.31M |
| Total Liabilities | 1.10B | 1.14B | 892.33M | 835.26M | 874.11M | 399.35M |
| Stockholders Equity | 1.31B | 1.09B | 1.09B | 815.89M | 447.15M | 464.44M |
Cash Flow | ||||||
| Free Cash Flow | 509.73M | 354.05M | 493.13M | 258.70M | 263.43M | 41.78M |
| Operating Cash Flow | 537.93M | 390.14M | 544.75M | 305.26M | 281.78M | 53.92M |
| Investing Cash Flow | -281.03M | -627.17M | -226.01M | 5.94M | -276.55M | 3.68M |
| Financing Cash Flow | -218.69M | -316.58M | -118.54M | -13.06M | 311.69M | -39.33M |
Lantheus Technical Analysis
Neutral
104.82
Price Trends
103.97
Negative
95.93
Positive
81.20
Positive
Market Momentum
-0.90
Positive
43.26
Neutral
17.58
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LNTH, the sentiment is Neutral. The current price of 104.82 is above the 20-day moving average (MA) of 101.79, above the 50-day MA of 103.97, and above the 200-day MA of 81.20, indicating a neutral trend. The MACD of -0.90 indicates Positive momentum. The RSI at 43.26 is Neutral, neither overbought nor oversold. The STOCH value of 17.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LNTH.
Lantheus Risk Analysis
Lantheus disclosed 67 risk factors in its most recent earnings report. Lantheus reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lantheus Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $6.59B | 23.97 | 23.27% | ― | 2.35% | 7.38% | |
70 Outperform | $1.75B | 15.73 | 19.19% | ― | 30.90% | ― | |
66 Neutral | $2.23B | 124.26 | 1.43% | ― | -8.81% | -96.21% | |
60 Neutral | $5.88B | 37.03 | -326.75% | ― | 9.28% | 4917.17% | |
56 Neutral | $2.81B | -25.50 | -10.42% | ― | 24.85% | -264.42% | |
54 Neutral | $1.78B | -1.03 | -55.97% | 11.50% | -4.18% | -2138.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
LNTH
Lantheus
100.26
45.11
81.80%
PRGO
Perrigo Company
12.97
-8.77
-40.35%
SUPN
Supernus Pharmaceuticals
49.03
7.03
16.74%
ANIP
ANI Pharmaceuticals
76.87
-13.25
-14.70%
HCM
HUTCHMED
12.64
-3.57
-22.02%
AMRX
Amneal Pharmaceuticals
18.19
8.86
94.96%
Lantheus Corporate Events
Business Operations and StrategyDelistings and Listing ChangesM&A Transactions
Curium to Acquire Lantheus, Taking Company Private
Positive
Aug 4, 2026
On August 3, 2026, Lantheus agreed to be acquired by Curium US Holdings via a merger that will take Lantheus private as a wholly owned subsidiary, with shareholders receiving $102.50 in cash per share plus a non-tradeable contingent value right of...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Curium to Acquire Lantheus in $8 Billion Merger
Positive
Aug 3, 2026
On August 3, 2026, Curium US Holdings and Lantheus agreed to a merger in which Curium will acquire all Lantheus shares for $102.50 in cash at closing, plus up to $12.00 per share in non-transferable contingent value rights tied to 2030 sales miles...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.